Skip to main content

Suction-Assisted Protein Lipectomy (SAPL / Liposuction) for Lymphedema

SAPL (also called lymphedema liposuction) is a minimally invasive reductive / debulking operation that targets the solid, non-fluid component of chronic lymphedema — the hypertrophied fibroadipose tissue that accumulates in late-stage disease and cannot be removed by compression or physiologic surgery. Pioneered by Håkan Brorson in Sweden in 1987, SAPL achieves excess-volume reductions of 91–117% in extremity lymphedema but requires lifelong postoperative compression because it does not address the underlying lymphatic dysfunction.[1][2][3] A 2025 meta-analysis (52 studies, 2,334 patients) confirmed that standalone liposuction reduces limb volume by 99.74%, while combined approaches with LVA / VLNT achieve 87.31% but significantly decrease compression dependence.[3]

For the broader condition see Genital Lymphedema and Giant Penoscrotal Lymphedema. For physiologic SCIP-based options see LYST, 3R / SCIP-LFT, Complete Functional Lymphatic-System Pedicled Transfer, CHASCIP, LVA, and VLNT; for open excisional debulking see Modified Charles Procedure and Debulking Scrotoplasty; for the conservative anchor see Complex Decongestive Therapy.

Definition and Terminology​

The term Suction-Assisted Protein Lipectomy (SAPL) was coined by Granzow et al. to distinguish lymphedema liposuction from cosmetic liposuction — emphasizing that the procedure removes protein-rich fibrotic tissue, the hallmark of chronic lymphedema, not merely fat.[4] Synonymous terms in the literature include:

  • Suction-assisted lipectomy (SAL)
  • Circumferential suction-assisted lipectomy (CSAL)
  • Power-assisted liposuction (PAL)
  • Dry liposuction (no tumescent fluid)
  • Debulking liposuction

All refer to circumferential removal of hypertrophied subcutaneous fibroadipose tissue through small cannula incisions.[2][5][6]

Pathophysiologic Rationale — The Two-Component Model​

Understanding SAPL requires the two-component model of lymphedema:[3][4][7]

ComponentStageCharacteristicsResponse to therapy
FluidISL I – early IIPitting edema; protein-rich interstitial fluid; compressibleResponds to CDT, compression, LVA, VLNT
Solid (fibroadipose)ISL late II – IIINon-pitting; adipose hypertrophy + fibrosis + protein depositionNot removable by CDT or physiologic surgery — only by lipectomy or excision

Chronic lymph stasis drives a cascade of pathologic changes — adipose hypertrophy, collagen deposition, protein accumulation — producing a firm, non-compressible tissue envelope. Lymphedema-associated adipose tissue (LAT) shows an upregulated inflammatory response and adipogenic / lymphangiogenic signature distinct from obesity-induced adipose tissue.[8] Koc et al. showed LAT has higher basal lipolysis, increased (lymph)angiogenic capacity, and elevated inflammatory cytokine secretion, and that LAT-derived fluid improved adipogenic conversion of preadipocytes — a self-perpetuating cycle broken only by physical removal of the tissue.[9]

LVA and VLNT can restore lymphatic flow but cannot remove already-deposited fibroadipose tissue.[3][7][10]

Indications​

Per AAPS consensus and AVF / AVLS / SVM expert-opinion consensus:[2][4][11]

  • ISL late Stage II or Stage III non-pitting lymphedema — solid component predominates.
  • Failed conservative therapy with CDT maximized.
  • Unilateral lymphedema with ≥ 25% volume difference vs the contralateral limb.
  • Symptoms of discomfort, intractable pain, and / or dysfunction from limb size / weight.
  • Recurrent cellulitis — SAPL reduces cellulitis rates from 58% to 15% (p < 0.0001).[4]
  • Patient dissatisfaction with conservative measures.

Contraindications / poor candidates

  • Predominantly pitting edema (fluid component) — treat first with physiologic surgery (LVA / VLNT), not liposuction.[7]
  • Active cellulitis or skin infection.
  • Inability to comply with lifelong compression — absolute requirement for standalone SAPL.[2][12][13]
  • Bilateral lymphedema — relative; no normal contralateral limb for volume comparison.

Preoperative Evaluation​

Per the Brorson protocol implemented by Granoff et al.:[1]

  • Lymphedema-therapist confirmation that CDT has been maximized.
  • Circumferential volume measurement at standardized intervals to compute excess volume.
  • ICG lymphography to assess residual lymphatic function and decide whether LVA should precede / follow / accompany liposuction.
  • Bioimpedance spectroscopy (L-Dex) to quantify extracellular fluid and distinguish fluid from solid components.
  • MRI / CT to map fibroadipose distribution.
  • Custom compression garments ordered preoperatively, available for immediate postoperative application.

Surgical Technique — Brorson Protocol​

The most widely adopted technique worldwide; implemented in the US by Granoff et al.[1][5][14]

Step 1 — Anesthesia and tourniquet​

  • General anesthesia.
  • Pneumatic tourniquet on the upper arm (UE) or thigh (LE when feasible) to create a bloodless field — minimizes blood loss and allows the surgeon to distinguish aspirated fat from blood.

Step 2 — Incisions​

  • Multiple small (3–4 mm) stab incisions circumferentially along the entire affected limb, at 5–10 cm intervals, allowing access to all subcutaneous compartments.

Step 3 — Liposuction​

  • A 3–4 mm metallic cannula attached to vacuum suction is advanced in a circumferential, radial pattern through subcutaneous tissue.
  • No tumescent fluid in the original Brorson "dry" technique[5] — rationale: tumescent fluid obscures the volume endpoint and may damage remaining lymphatic vessels.
  • Power-assisted liposuction (PAL) with a vibrating cannula tip reduces surgeon fatigue and may be gentler on tissues.[1]
  • Wet, superwet, laser-assisted, and water-assisted variants exist; no consensus on which is most effective.[5]
  • Aspiration continues until the limb volume matches the contralateral limb; the surgeon works distal to proximal, systematically debulking each segment.

Step 4 — Immediate compression​

  • Before the tourniquet is released, custom-fitted compression garments are applied to the limb — the most critical step. Compression must be in place before reperfusion to prevent hematoma formation and immediate re-accumulation of fluid.
  • Compression bandaging is added over the garments.

Step 5 — Lifelong postoperative compression​

  • Mandatory.[2][12][13]
  • Yoshida et al. — threshold pressures >40 mmHg on the lower leg and >20 mmHg on the thigh, best achieved with combined stockings + bandaging (SB group) for the first 6 months.[12]
  • After 6 months, pressure can be decreased if volume reduction is maintained.[12]
  • Success was significantly higher with combined SB than with stockings alone or bandaging alone.[12]

Clinical Outcomes — Standalone SAPL​

SeriesnExtremityFollow-upExcess-volume reductionKey finding
Brorson & Svensson (prospective comparative)[1]28UE—104% (liposuction + compression) vs 47% (compression alone)First prospective comparison demonstrating superiority
Hoffner et al. (prospective)[1]105UE + LE5 y117%Largest prospective series; max reduction at 5 y
Boyages et al.[1]21UE + LE6 moUE 44.2% → 3.6%; LE 47.3% → 4.3%All patients reported improved function and symptoms
Granoff et al. (US implementation)[1]39 (41 procedures)23 UE / 18 LE1 yUE 116%; LE 115%QOL ↑ 33%; cellulitis ↓; reliance on conservative therapy ↓
Karlsson et al. (ALERT, Australia)[14]5929 UE / 30 LE5 yUE 1,061 → 22 mL; LE 3,447 → 669 mLUE durable; LE partial recurrence
Lamprou et al. (CSAL)[15]88LE2 yPrimary 79%; Secondary 101%Secondary LE responded better than primary
Stewart & Munnoch (single surgeon, 9 y)[16]69 (72 legs)LEup to 5 y85% at 3 mo → 90% at 5 yMean aspirate 4,550 mL; no major complications; primary male LE had poorest outcomes
Granzow et al. (SAPL)[4]10UE + LE—LE 3,212 mL; UE 943 mL (87–111%)Cellulitis 58% → 15% (p < 0.0001)

Greene et al. reported that liposuction of the leg (ankle to thigh) resulted in resolution of foot edema despite the foot not being surgically treated, with markedly reduced dermal backflow on lymphoscintigraphy at 4 y — suggesting physiologic effects beyond simple tissue removal.[17]

Meta-Analysis — Chen et al. 2025 (52 studies, 2,334 patients)​

ParameterStandalone liposuctionCombined liposuction + LVA / VLNT
Volume reduction (UE)91.08%—
Volume reduction (LE)92.03%—
Overall volume reduction99.74%87.31%
Compression dependenceContinuous (lifelong)Significantly decreased
Lymphatic functionNot improvedImproved
Infection reductionYesYes
QOL improvementYesEnhanced
[3]

Key finding: standalone liposuction achieves slightly greater volume reduction but requires continuous compression; combined approaches trade a small volume-reduction decrement for significantly decreased compression dependence and improved lymphatic function.[3]

Combined SAPL + Physiologic Surgery — The "3L" Strategy​

Brazio & Nguyen treatment algorithm (2021)​

Staging-based algorithm combining liposuction with physiologic procedures:[7]

PresentationSequencing
Predominantly non-pitting (solid)Liposuction first → LVA / VLNT to restore drainage and prevent progression
Predominantly pitting (fluid)Physiologic procedure first → selective liposuction as a second stage if residual fibroadipose tissue
MixedSingle-stage combination (simultaneous liposuction + LVA / VLNT)

Results: all groups achieved 82–106% excess-volume reduction, maintained up to 2.4 y. Mean postoperative compression duration 12.5 → 7.5 h/day (p = 0.003). Ten of 11 patients with prior cellulitis had no further recurrence.[7]

Chen et al. ISTL algorithm (2025)​

The Integrated Surgical Treatment for Lymphedema (ISTL) algorithm proposes a component-based, individualized "3L" framework combining LVA + VLNT + liposuction tailored to disease severity, pathological tissue composition, and lymphatic functionality.[18]

AAPS consensus (Grade 1C)​

The AAPS consensus conference concluded that debulking procedures such as liposuction are effective for addressing the non-fluid component of lymphedema (Grade 1C), and that there is a role for liposuction combined with physiologic procedures, although the timing of each procedure is currently unresolved (Grade 1C).[11]

SAPL vs Open Excisional Procedures (Charles)​

FeatureSAPL / LiposuctionCharles Procedure
InvasivenessMinimally invasive (3–4 mm incisions)Major open surgery (circumferential excision to deep fascia)
Skin preservationYesNo — excised and replaced with skin graft
Cosmetic outcomeExcellent — natural skin contourPoor — graft appearance, scarring, contracture
ComplicationsMinimalHigh (dehiscence, graft loss, infection, lymphorrhea)
Hospital stayOutpatient or 1-day admissionProlonged
RecoveryDaysWeeks to months
Volume reduction85–117%Variable (depends on extent of excision)
Postop compressionLifelong requiredVariable
Lymphatic functionNot improved (may be preserved)Destroyed (superficial lymphatics excised)
IndicationNon-pitting, fibroadipose predominantGiant elephantiasis with massive skin excess
[1][2][4][10][16][19]

The AVF / AVLS / SVM consensus reserves Charles-type open debulking for the most advanced cases, with surgical treatment shifting toward the less invasive liposuction approach.[2]

Possible Physiologic Effects Beyond Volume Reduction​

Greene et al.'s observation (foot edema resolution despite no foot intervention, reduced lymphoscintigraphic dermal backflow at 4 y) suggests SAPL may have effects beyond tissue removal:[17]

  1. Reduced lymph production — removing hypertrophied adipose decreases metabolic demand and interstitial-fluid production in the treated segment.
  2. Improved blood flow — decompression of the subcutaneous compartment may improve arterial inflow and venous return.
  3. Enhanced superficial-to-deep lymphatic connections — removal of fibrotic tissue may unmask or improve crossings between superficial and deep systems.
  4. Reduced inflammatory milieu — removing cytokine-secreting LAT may break the cycle of inflammation → adipose hypertrophy → further lymphatic impairment.[8][9]

Postoperative Compression — The Critical Requirement​

Lifelong compression therapy is mandatory after standalone SAPL — the single most important postoperative requirement and the primary limitation of the technique.[2][12][13]

Yoshida et al. provided the most detailed analysis:[12]

  • Threshold pressures: >40 mmHg on the lower leg, >20 mmHg on the thigh.
  • Optimal method: combined stockings + bandaging for the first 6 months.
  • Success rate significantly higher with combined stockings + bandaging than with either alone.
  • After 6 months, pressure can be decreased without loss of volume reduction.
  • Without compression, volume recurs — the underlying lymphatic dysfunction persists.

The Cochrane review confirms that lifelong compression garments are needed to prevent postoperative recurrence.[13]

SAPL in Genital Lymphedema — Limited Role​

Application of SAPL to genital lymphedema is notably limited compared with extremity disease, for several reasons:[20]

  • Anatomic constraints — thin, mobile scrotal / penile skin and limited subcutaneous fat make circumferential cannula-based liposuction technically difficult.
  • Disease pathology — ISL Stage III genital lymphedema is characterized by massive fibrosis, lymphorrhea, and skin changes (verrucous hyperplasia, papillomatosis) that extend beyond the subcutaneous fat layer.
  • Compression challenges — lifelong compression of the genitalia is impractical compared with extremity garments.
  • Excisional approaches preferred — debulking scrotoplasty, Charles procedure, and SCIP-LFT can remove the entire diseased tissue envelope (skin + subcutaneous tissue + fibrotic tissue).

Torio-Padron et al. described an integrated concept for male genital lymphedema (n = 51) combining perioperative CDT with open surgical debulking (excision + primary closure) — not liposuction — achieving low complications (4% hematoma, 2% dehiscence) and improved GBI QOL.[20]

A limited adjunctive role for SAPL in genital lymphedema may exist for:

  • Early-stage (ISL I–II) genital disease with predominantly fibroadipose deposition and minimal skin changes.
  • Adjunctive debulking of the mons pubis or proximal thigh in patients with combined genital + lower-extremity disease.
  • Combination with physiologic surgery (LVA, VLNT, SCIP-LYST) addressing the solid component while the physiologic procedure addresses drainage.

Liposuction Technique Variations​

TechniqueDescriptionAdvantagesDisadvantages
Dry liposuction (Brorson original)No tumescent fluid; cannula aspiration onlyNo fluid distortion of endpoint; potentially less lymphatic-vessel damageHigher blood loss; more surgeon effort
Power-assisted (PAL)Vibrating cannula tip; no tumescentReduced surgeon fatigue; potentially gentler on tissuesEquipment cost
Wet / SuperwetTumescent fluid (lidocaine + epinephrine) before aspirationReduced blood loss; local-anesthesia effectFluid distorts endpoint; may damage lymphatics
Laser-assistedLaser energy liquefies fat before aspirationPotentially easier aspirationThermal injury risk; limited LE evidence
Water-assisted (WAL)Pulsatile water jet dislodges fatGentle tissue handling; selective fat removalLimited LE evidence
[1][5]

No consensus exists on which liposuction technique is most effective for lymphedema; the dry / PAL Brorson protocol has the most extensive evidence base.[5]

Long-Term Durability​

Karlsson et al. (ALERT, 5 y) provides the most informative long-term data:[14]

  • Upper extremity: median volume difference 1,061 mL preop → 79 mL at 1 y → 22 mL at 5 y — excellent durable results that actually improved over time.
  • Lower extremity: median volume difference 3,447 mL → 263 mL at 1 y → 669 mL at 5 y — partial recurrence in the legs.

Differential durability between arms and legs likely reflects the greater gravitational challenge in the LE and the difficulty of maintaining adequate compression. Stewart & Munnoch similarly reported that primary male LE had the poorest outcomes; secondary lymphedema responded best.[16]

Key Takeaways​

  1. SAPL targets the solid (fibroadipose) component of chronic lymphedema that cannot be removed by compression, CDT, or physiologic surgery — the only minimally invasive option for non-pitting, late-stage disease.[2][3][10]
  2. Excess-volume reductions of 85–117% are consistently achieved; the Brorson protocol is the most widely validated technique.[1][2][14][15]
  3. Lifelong postoperative compression is mandatory — without it, volume recurs because SAPL does not restore lymphatic function. Threshold pressures: >40 mmHg (lower leg) and >20 mmHg (thigh).[12][13]
  4. Combined SAPL + physiologic surgery (LVA / VLNT) achieves slightly lower volume reduction (87.31%) but significantly decreases compression dependence and improves lymphatic function — the "3L" strategy.[3][7][18]
  5. Cellulitis rates decrease dramatically (58% → 15%, p < 0.0001).[4]
  6. SAPL has limited applicability to genital lymphedema — anatomic constraints, compression challenges, and the predominance of fibrosis / skin changes make excisional approaches more appropriate for advanced genital disease.[20]
  7. Upper-extremity results are more durable than lower-extremity at 5 y (22 mL vs 669 mL residual volume difference).[14]
  8. AAPS consensus rates liposuction as Grade 1C for the non-fluid component, with a Grade 1C role for combination with physiologic procedures (timing unresolved).[11]

References​

1. Granoff MD, Johnson AR, Shillue K, et al. A single institution multi-disciplinary approach to power-assisted liposuction for the management of lymphedema. Ann Surg. 2022;276(5):e613–e621. doi:10.1097/SLA.0000000000004588

2. Lurie F, Malgor RD, Carman T, et al. The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment. Phlebology. 2022;37(4):252–266. doi:10.1177/02683555211053532

3. Chen J, Feng X, Zhou Y, et al. Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis. Front Oncol. 2025;15:1651472. doi:10.3389/fonc.2025.1651472

4. Granzow JW, Soderberg JM, Kaji AH, Dauphine C. An effective system of surgical treatment of lymphedema. Ann Surg Oncol. 2014;21(4):1189–1194. doi:10.1245/s10434-014-3515-y

5. Sollie M, Lilja C, Ydo CB, et al. Dry liposuction for upper-extremity end-stage lymphedema: a step-by-step video of technique. Aesthetic Plast Surg. 2026. doi:10.1007/s00266-026-05745-y

6. Garza R, Skoracki R, Hock K, Povoski SP. A comprehensive overview on the surgical management of secondary lymphedema of the upper and lower extremities related to prior oncologic therapies. BMC Cancer. 2017;17(1):468. doi:10.1186/s12885-017-3444-9

7. Brazio PS, Nguyen DH. Combined liposuction and physiologic treatment achieves durable limb volume normalization in class II-III lymphedema: a treatment algorithm to optimize outcomes. Ann Plast Surg. 2021;86(5S Suppl 3):S384–S389. doi:10.1097/SAP.0000000000002695

8. Karaman S, Lehti S, Zhang C, et al. Multi-omics characterization of lymphedema-induced adipose tissue resulting from breast cancer-related surgery. FASEB J. 2024;38(20):e70097. doi:10.1096/fj.202400498RR

9. Koc M, Wald M, Varaliová Z, et al. Lymphedema alters lipolytic, lipogenic, immune and angiogenic properties of adipose tissue: a hypothesis-generating study in breast cancer survivors. Sci Rep. 2021;11(1):8171. doi:10.1038/s41598-021-87494-3

10. Schaverien MV, Coroneos CJ. Surgical treatment of lymphedema. Plast Reconstr Surg. 2019;144(3):738–758. doi:10.1097/PRS.0000000000005993

11. Chang DW, Dayan J, Greene AK, et al. Surgical treatment of lymphedema: a systematic review and meta-analysis of controlled trials. Results of a consensus conference. Plast Reconstr Surg. 2021;147(4):975–993. doi:10.1097/PRS.0000000000007783

12. Yoshida S, Koshima I, Imai H, et al. Effect of postoperative compression therapy on the success of liposuction in patients with advanced lower limb lymphedema. J Clin Med. 2021;10(21):4852. doi:10.3390/jcm10214852

13. Markkula SP, Leung N, Allen VB, Furniss D. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Cochrane Database Syst Rev. 2019;2:CD011433. doi:10.1002/14651858.CD011433.pub2

14. Karlsson T, Mackie H, Koelmeyer L, et al. Liposuction for advanced lymphedema in a multidisciplinary team setting in Australia: 5-year follow-up. Plast Reconstr Surg. 2024;153(2):482–491. doi:10.1097/PRS.0000000000010612

15. Lamprou DA, Voesten HG, Damstra RJ, Wikkeling OR. Circumferential suction-assisted lipectomy in the treatment of primary and secondary end-stage lymphoedema of the leg. Br J Surg. 2017;104(1):84–89. doi:10.1002/bjs.10325

16. Stewart CJ, Munnoch DA. Liposuction as an effective treatment for lower extremity lymphoedema: a single surgeon's experience over nine years. J Plast Reconstr Aesthet Surg. 2018;71(2):239–245. doi:10.1016/j.bjps.2017.11.003

17. Greene AK, Voss SD, Maclellan RA. Liposuction for swelling in patients with lymphedema. N Engl J Med. 2017;377(18):1788–1789. doi:10.1056/NEJMc1709275

18. Chen J, Chen Z, Wu X, et al. Integrated surgical treatment: a new model for treating secondary extremity lymphedema based on algorithms. Front Oncol. 2025;15:1676803. doi:10.3389/fonc.2025.1676803

19. Sanka SA, Chryssofos S, Anolik RA, Sacks JM. Advances in surgical management of chronic lymphedema: current strategies and future directions. Med Oncol. 2025;42(2):44. doi:10.1007/s12032-024-02576-2

20. Torio-Padron N, Stark GB, Földi E, Simunovic F. Treatment of male genital lymphedema: an integrated concept. J Plast Reconstr Aesthet Surg. 2015;68(2):262–268. doi:10.1016/j.bjps.2014.10.003